Endocrinol Metab.
2025 Feb;40(1):156-160. 10.3803/EnM.2024.2150.
Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
- 2Institute of Clinical Chemistry and Laboratory Medicine, University Greifswald, Greifswald, Germany
- 3Diabetes, Endocrinology, Metabolism Section, Katholisches Klinikum Bochum, St. Josef Hospital, Ruhr-University, Bochum, Germany
- 4Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- KMID: 2565263
- DOI: http://doi.org/10.3803/EnM.2024.2150
Abstract
- In the context of a global shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, we assessed the impact of discontinuing dulaglutide on metabolic control in individuals with type 2 diabetes. Our analysis included data from 69 individuals and revealed a significant deterioration in glycemic control following the discontinuation. Specifically, the average hemoglobin A1c level increased from 7.0%±0.9% to 8.1%±1.4% (P<0.001), and fasting glucose levels rose from 129±31 to 156±50 mg/dL (P<0.001) within 3 months after stopping the medication. Alternative treatments such as dipeptidyl peptidase-4 inhibitors and sodium glucose cotransporter- 2 inhibitors were insufficient substitutes, highlighting the essential role of continuous GLP-1 receptor agonist therapy in maintaining metabolic health.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Mechanisms of Glucagon Receptor Agonism and GLP-1/Glucagon/GIP Receptor Triple Agonism for Treatment of Diabetes and Obesity
- The Global Shortage of Glucagon-Like Peptide-1 Receptor Agonists
- Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
- Glucagon-Like Peptide-1 (GLP-1) Agonist
- Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018
